{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T00:24:33Z","timestamp":1792455873445,"version":"4.5.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007128","name":"Natural Science Foundation of Shaanxi Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tralokinumab, a humanized monoclonal antibody targeting interleukin-13, has been primarily used for the treatment of moderate-to-severe atopic dermatitis. Given its extensive use in clinical practice, understanding its safety profile in the real-world setting is crucial.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study utilized disproportionality analysis to evaluate the safety of tralokinumab in clinical practice by analyzing all adverse event reports since 2021 in the FDA Adverse Event Reporting System database that identified tralokinumab as the primary suspected drug. Reporting odds ratio, proportional reporting ratio, multi-item gamma Poisson shrinker, and Bayesian confidence propagation neural network were used for disproportionality analyses of adverse events related to tralokinumab. Additionally, the Weibull distribution was employed to model the risk of adverse events over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Adverse reactions documented on the drug label, such as injection site reactions, conjunctivitis, and upper respiratory infections, displayed positive signals. Additionally, potential adverse reactions not mentioned on the label were also identified, including dizziness, headache, nausea, vomiting, hair loss, and acne. The importance of adverse event monitoring, particularly in the first month after treatment initiation, was emphasized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study has provided preliminary safety data on the real-world application of tralokinumab, confirming some known adverse reactions and revealing additional potential risks. The findings offer critical safety information for clinicians prescribing tralokinumab to treat atopic dermatitis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2024.1458438","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T16:38:24Z","timestamp":1723739904000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["Assessing the real-world safety of tralokinumab for atopic dermatitis: insights from a comprehensive analysis of FAERS data"],"prefix":"10.3389","volume":"15","author":[{"given":"Kaidi","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengxiang","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"adv00051","DOI":"10.2340\/00015555-3409","article-title":"Psychosocial aspects of adult acne: data from 13 European countries","volume":"100","author":"Altunay","year":"2020","journal-title":"Acta Derm. Venereol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1517\/14740338.2016.1167184","article-title":"Data mining spontaneous adverse drug event reports for safety signals in Singapore - a comparison of three different disproportionality measures","volume":"15","author":"Ang","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/s2213-2600(15)00197-6","article-title":"Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial","volume":"3","author":"Brightling","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1800948","DOI":"10.1183\/13993003.00948-2018","article-title":"Tralokinumab did not demonstrate oral corticosteroid-sparing effects in severe asthma","volume":"53","author":"Busse","year":"2019","journal-title":"Eur. Respir. J."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.20211","article-title":"Psychosocial and mental impact of alopecia areata: analysis of the Danish Skin Cohort","author":"Clemmesen","year":"2024","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s13555-022-00864-1","article-title":"The association of alopecia areata-related emotional symptoms with work productivity and daily activity among patients with alopecia areata","volume":"13","author":"Gandhi","year":"2023","journal-title":"Dermatol Ther. (Heidelb)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1093\/bjd\/ljad054","article-title":"Beyond health-related quality of life: initial psychometric validation of a new scale for addressing the gap in assessing the full range of alopecia areata psychosocial burden","volume":"189","author":"Gorbatenko-Roth","year":"2023","journal-title":"Br. J. Dermatol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1111\/bjd.20832","article-title":"Tralokinumab plus topical corticosteroids in adults with severe atopic dermatitis and inadequate response to or intolerance of ciclosporin A: a placebo-controlled, randomized, phase III clinical trial (ECZTRA 7)","volume":"186","author":"Gutermuth","year":"2022","journal-title":"Br. J. Dermatol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"i11","DOI":"10.1093\/bjd\/ljad251","article-title":"Is it really ever 'just acne'? Considering the psychodermatology of acne","volume":"189","author":"Hughes","year":"2023","journal-title":"Br. J. Dermatol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"104763","DOI":"10.1016\/j.jstrokecerebrovasdis.2020.104763","article-title":"Dupilumab for atopic dermatitis, a possible risk factor of juvenile ischemic stroke: a case report","volume":"29","author":"Iwase","year":"2020","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"B12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1080\/14740338.2023.2189698","article-title":"Adverse effects of proton pump inhibitors (PPIs) on the renal system using data mining algorithms (DMAs)","volume":"22","author":"Jain","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B13","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/s0140-6736(20)31286-1","article-title":"Atopic dermatitis","volume":"396","author":"Langan","year":"2020","journal-title":"Lancet"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.3390\/life13061419","article-title":"Atopic dermatitis: disease features, therapeutic options, and a multidisciplinary approach","volume":"13","author":"Lugovi\u0107-Mihi\u0107","year":"2023","journal-title":"Life (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1501","DOI":"10.1111\/all.16009","article-title":"Treatment of atopic dermatitis: recently approved drugs and advanced clinical development programs","volume":"79","author":"M\u00fcller","year":"2024","journal-title":"Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1111\/jdv.18926","article-title":"The burden of alopecia areata: a scoping review focusing on quality of life, mental health and work productivity","volume":"37","author":"Muntyanu","year":"2023","journal-title":"J. Eur. Acad. Dermatol Venereol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jmb.2016.12.005","article-title":"Structural characterisation reveals mechanism of IL-13-neutralising monoclonal antibody tralokinumab as inhibition of binding to IL-13r\u03b11 and IL-13r\u03b12","volume":"429","author":"Popovic","year":"2017","journal-title":"J. Mol. Biol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"3260","DOI":"10.1210\/jc.2009-2546","article-title":"Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children","volume":"95","author":"Rivkees","year":"2010","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"B19","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/ane.13690","article-title":"Identification of novel signal of clobazam-associated drug reaction with eosinophilia and systemic symptoms syndrome: a disproportionality analysis","volume":"146","author":"Sharma","year":"2022","journal-title":"Acta Neurol. Scand."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e28671","DOI":"10.1002\/jmv.28671","article-title":"Association of antiviral drugs and their possible mechanisms with DRESS syndrome using data mining algorithms","volume":"95","author":"Sharma","year":"2023","journal-title":"J. Med. Virol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/clep.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"","journal-title":"Clin. Epidemiol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1111\/bjd.19573","article-title":"Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial","volume":"184","author":"Silverberg","year":"2021","journal-title":"Br. J. Dermatol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/bjd.20810","article-title":"Conjunctivitis in adult patients with moderate-to-severe atopic dermatitis: results from five tralokinumab clinical trials","volume":"186","author":"Wollenberg","year":"2022","journal-title":"Br. J. Dermatol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/bjd.19574","article-title":"Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2)","volume":"184","author":"Wollenberg","year":"2021","journal-title":"Br. J. Dermatol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.jaci.2018.05.029","article-title":"Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb","volume":"143","author":"Wollenberg","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"923362","DOI":"10.3389\/fimmu.2022.923362","article-title":"The efficacy and safety of IL-13 inhibitors in atopic dermatitis: a systematic review and meta-analysis","volume":"13","author":"Zhang","year":"2022","journal-title":"Front. Immunol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1458438\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T16:38:28Z","timestamp":1723739908000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2024.1458438\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":28,"alternative-id":["10.3389\/fphar.2024.1458438"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2024.1458438","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"article-number":"1458438"}}